{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:17:41Z","timestamp":1791267461978,"version":"4.1.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T00:00:00Z","timestamp":1712966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T00:00:00Z","timestamp":1712966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Alma Mater Studiorum - Universit\u00e0 di Bologna"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Fabry Disease (FD) is a genetic disease caused by a deficiency in the activity of lysosomal galactosidase A (\u03b1-GalA), an enzyme responsible for the catabolism of globotriaosylceramide (Gb3). Since lysosomes are present throughout the body and play a crucial role in catabolism and recycling of cytosolic compounds, FD can affect multiple organs and result in various symptoms, including renal, cardiovascular, neurological, cutaneous, and ophthalmic manifestations. Due to the nonspecific symptoms and the rarity of FD, it is often diagnosed late in life. However, introducing targeted therapies such as enzyme replacement therapy (ERT) and chaperone therapy has significantly improved FD's natural history and prognosis by restoring \u03b1-GalA enzyme activity. Despite the advancements, there are limitations to the currently available therapies, which has prompted research into new potential treatments for FD, including alternative forms of enzyme replacement therapy, substrate reduction therapy, mRNA therapy, and genetic therapy. In this review, we analyze the epidemiology, pathophysiology, and treatment of FD, with particular emphasis on promising therapeutic opportunities that could shift the treatment of this rare disease from a standardized to a personalized approach soon.<\/jats:p>","DOI":"10.1007\/s11255-024-04042-4","type":"journal-article","created":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T09:01:51Z","timestamp":1712998911000},"page":"3161-3172","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Fabry disease: a rare disorder calling for personalized medicine"],"prefix":"10.1007","volume":"56","author":[{"given":"Sarah","family":"Lerario","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Monti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Ambrosetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnese","family":"Luglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pietra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Aiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Montanari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Bellasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluigi","family":"Zaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Galante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Salera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Capelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"La Manna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Provenzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,13]]},"reference":[{"issue":"5","key":"4042_CR1","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1093\/ckj\/sfw082","volume":"9","author":"R Mignani","year":"2016","unstructured":"Mignani R, Pieruzzi F, Berri F, Burlina A, Chinea B, Gallieni M et al (2016) Fabry STabilization indEX (FASTEX): an innovative tool for the assessment of clinical stabilization in fabry disease. Clin Kidney J 9(5):739\u2013747","journal-title":"Clin Kidney J"},{"issue":"4","key":"4042_CR2","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1399-0004.2004.00219.x","volume":"65","author":"C Whybra","year":"2004","unstructured":"Whybra C, Kampmann C, Krummenauer F, Ries M, Mengel E, Miebach E et al (2004) The mainz severity score index: a new instrument for quantifying the anderson\u2013fabry disease phenotype and the response of patients to enzyme replacement therapy. Clin Genet 65(4):299\u2013307","journal-title":"Clin Genet"},{"issue":"2","key":"4042_CR3","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ymgme.2019.12.010","volume":"129","author":"M Lenders","year":"2020","unstructured":"Lenders M, Brand E (2020) FAbry STabilization indEX (FASTEX): clinical evaluation of disease progression in fabry patients. Mol Genet Metab 129(2):142\u2013149","journal-title":"Mol Genet Metab"},{"issue":"4","key":"4042_CR4","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","volume":"123","author":"A Ortiz","year":"2018","unstructured":"Ortiz A, Germain DP, Desnick RJ, Politei J, Mauer M, Burlina A et al (2018) Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet Metab 123(4):416\u2013427","journal-title":"Mol Genet Metab"},{"issue":"1","key":"4042_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms22010206","volume":"22","author":"O Azevedo","year":"2020","unstructured":"Azevedo O, Gago MF, Miltenberger-Miltenyi G, Sousa N, Cunha D (2020) Fabry disease therapy: state-of-the-art and current challenges. Int J Mol Sci 22(1):1\u201316","journal-title":"Int J Mol Sci"},{"issue":"9647","key":"4042_CR6","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","volume":"372","author":"YA Zarate","year":"2008","unstructured":"Zarate YA, Hopkin RJ (2008) Fabry\u2019s disease. Lancet 372(9647):1427\u20131435","journal-title":"Lancet"},{"issue":"2","key":"4042_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3390\/ijns9020031","volume":"9","author":"V Gragnaniello","year":"2023","unstructured":"Gragnaniello V, Burlina AP, Commone A, Gueraldi D, Puma A, Porc\u00f9 E et al (2023) Newborn screening for fabry disease: current status of knowledge. Int J Neonatal Screen 9(2):31. https:\/\/doi.org\/10.3390\/ijns9020031","journal-title":"Int J Neonatal Screen"},{"issue":"1","key":"4042_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1086\/504601","volume":"79","author":"M Spada","year":"2006","unstructured":"Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H et al (2006) High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet 79(1):31\u201340","journal-title":"Am J Hum Genet"},{"issue":"7","key":"4042_CR9","doi-asserted-by":"publisher","first-page":"951","DOI":"10.3390\/biom11070951","volume":"11","author":"V Gragnaniello","year":"2021","unstructured":"Gragnaniello V, Burlina AP, Polo G, Giuliani A, Salviati L, Duro G et al (2021) Newborn screening for fabry disease in northeastern Italy: results of five years of experience. Biomolecules 11(7):951","journal-title":"Biomolecules"},{"issue":"4","key":"4042_CR10","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1136\/jmg-2022-108523","volume":"60","author":"M Gilchrist","year":"2023","unstructured":"Gilchrist M, Casanova F, Tyrrell JS, Cannon S, Wood AR, Fife N et al (2023) Prevalence of fabry disease-causing variants in the UK biobank. J Med Genet 60(4):391\u2013396","journal-title":"J Med Genet"},{"issue":"12","key":"4042_CR11","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/gim.2016.55","volume":"18","author":"R Schiffmann","year":"2016","unstructured":"Schiffmann R, Fuller M, Clarke LA, Aerts JMFG (2016) Is it fabry disease? Genet Med 18(12):1181\u20131185","journal-title":"Genet Med"},{"issue":"2","key":"4042_CR12","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","volume":"81","author":"MH Branton","year":"2002","unstructured":"Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G et al (2002) Natural history of fabry renal disease: influence of alpha-galactosidase a activity and genetic mutations on clinical course. Medicine 81(2):122\u2013138","journal-title":"Medicine"},{"issue":"5","key":"4042_CR13","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/ASN.2016090964","volume":"28","author":"M Arends","year":"2017","unstructured":"Arends M, Wanner C, Hughes D, Mehta A, Oder D, Watkinson OT et al (2017) Characterization of classical and nonclassical fabry disease: a multicenter study. J Am Soc Nephrol 28(5):1631\u20131641","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"4042_CR14","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.jacc.2020.12.024","volume":"77","author":"M Pieroni","year":"2021","unstructured":"Pieroni M, Moon JC, Arbustini E, Barriales-Villa R, Camporeale A, Vujkovac AC et al (2021) Cardiac involvement in fabry disease: JACC review topic of the week. J Am Coll Cardiol 77(7):922\u2013936","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"4042_CR15","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.3390\/jcm9041116","volume":"9","author":"M Ivanova","year":"2020","unstructured":"Ivanova M (2020) Altered sphingolipids metabolism damaged mitochondrial functions: lessons learned from gaucher and fabry diseases. J Clin Med 9(4):1116","journal-title":"J Clin Med"},{"issue":"8","key":"4042_CR16","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1073\/pnas.0712309105","volume":"105","author":"JM Aerts","year":"2008","unstructured":"Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R et al (2008) Elevated globotriaosylsphingosine is a hallmark of fabry disease. Proc Natl Acad Sci U S A 105(8):2812\u20132817. https:\/\/doi.org\/10.1073\/pnas.0712309105","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"439","key":"4042_CR17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1651-2227.2002.tb03107.x","volume":"91","author":"F Birklein","year":"2002","unstructured":"Birklein F (2002) Mechanisms of neuropathic pain and their importance in fabry disease. Acta Paediatr Suppl 91(439):34\u201337","journal-title":"Acta Paediatr Suppl"},{"issue":"9","key":"4042_CR18","doi-asserted-by":"publisher","first-page":"e0204618","DOI":"10.1371\/journal.pone.0204618","volume":"13","author":"V Ravarotto","year":"2018","unstructured":"Ravarotto V, Carraro G, Pagnin E, Bertoldi G, Simioni F, Maiolino G et al (2018) Oxidative stress and the altered reaction to it in fabry disease: a possible target for cardiovascular-renal remodeling? PLoS ONE 13(9):e0204618. https:\/\/doi.org\/10.1371\/journal.pone.0204618","journal-title":"PLoS ONE"},{"issue":"9","key":"4042_CR19","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s10157-021-02058-z","volume":"25","author":"S Feriozzi","year":"2021","unstructured":"Feriozzi S, Rozenfeld P (2021) Pathology and pathogenic pathways in fabry nephropathy. Clin Exp Nephrol 25(9):925\u2013934","journal-title":"Clin Exp Nephrol"},{"issue":"8","key":"4042_CR20","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.numecd.2015.04.001","volume":"25","author":"L De Nicola","year":"2015","unstructured":"De Nicola L, Provenzano M, Chiodini P, D\u2019Arrigo G, Tripepi G, Del Vecchio L et al (2015) Prognostic role of LDL cholesterol in non-dialysis chronic kidney disease: multicenter prospective study in Italy. Nutr Metab Cardiovasc Dis 25(8):756\u2013762","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"8","key":"4042_CR21","doi-asserted-by":"publisher","first-page":"e0136442","DOI":"10.1371\/journal.pone.0136442","volume":"10","author":"YJ Jeon","year":"2015","unstructured":"Jeon YJ, Jung N, Park JW, Park HY, Jung SC (2015) Epithelial-mesenchymal transition in kidney tubular epithelial cells induced by globotriaosylsphingosine and globotriaosylceramide. PLoS ONE 10(8):e0136442","journal-title":"PLoS ONE"},{"issue":"1","key":"4042_CR22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1159\/000369309","volume":"129","author":"C T\u00f8ndel","year":"2015","unstructured":"T\u00f8ndel C, Kanai T, Larsen KK, Ito S, Politei JM, Warnock DG et al (2015) Foot process effacement is an early marker of nephropathy in young classic fabry patients without albuminuria. Nephron 129(1):16\u201321","journal-title":"Nephron"},{"issue":"1","key":"4042_CR23","first-page":"38","volume":"22","author":"RP Morrissey","year":"2011","unstructured":"Morrissey RP, Philip KJ, Schwarz ER (2011) Cardiac abnormalities in anderson-fabry disease and fabry\u2019s cardiomyopathy. Cardiovasc J Afr 22(1):38","journal-title":"Cardiovasc J Afr"},{"issue":"2","key":"4042_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biom11020194","volume":"11","author":"M Andreucci","year":"2021","unstructured":"Andreucci M, Provenzano M, Faga T, Michael A, Patella G, Mastroroberto P et al (2021) Aortic aneurysms chronic kidney disease and metalloproteinases. Biomolecules 11(2):1\u201313","journal-title":"Biomolecules"},{"key":"4042_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094434","author":"O Azevedo","year":"2021","unstructured":"Azevedo O, Cordeiro F, Gago MF, Miltenberger-miltenyi G, Ferreira C, Sousa N et al (2021) Fabry disease and the heart: a comprehensive review. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22094434","journal-title":"Int J Mol Sci"},{"key":"4042_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065246","author":"E Cort\u00e9s-Saladelafont","year":"2023","unstructured":"Cort\u00e9s-Saladelafont E, Fern\u00e1ndez-Mart\u00edn J, Fabry OS (2023) Disease and central nervous system involvement: from big to small, from brain to synapse. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24065246","journal-title":"Int J Mol Sci"},{"issue":"7","key":"4042_CR27","doi-asserted-by":"publisher","first-page":"e0180581","DOI":"10.1371\/journal.pone.0180581","volume":"12","author":"R Liguori","year":"2017","unstructured":"Liguori R, Incensi A, De Pasqua S, Mignani R, Fileccia E, Santostefano M et al (2017) Skin globotriaosylceramide 3 deposits are specific to fabry disease with classical mutations and associated with small fibre neuropathy. PLoS ONE 12(7):e0180581","journal-title":"PLoS ONE"},{"issue":"5","key":"4042_CR28","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/mus.27196","volume":"63","author":"K von Cossel","year":"2021","unstructured":"von Cossel K, Muschol N, Friedrich RE, Glatzel M, Ammer L, Lohm\u00f6ller B et al (2021) Assessment of small fiber neuropathy in patients carrying the non-classical Fabry variant p.D313Y. Muscle Nerve 63(5):745\u2013750. https:\/\/doi.org\/10.1002\/mus.27196","journal-title":"Muscle Nerve"},{"key":"4042_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-10-38","author":"M Biegstraaten","year":"2010","unstructured":"Biegstraaten M, van Schaik IN, Wieling W, Wijburg FA, Hollak CEM (2010) Autonomic neuropathy in fabry disease: a prospective study using the autonomic symptom profile and cardiovascular autonomic function tests. BMC Neurol. https:\/\/doi.org\/10.1186\/1471-2377-10-38","journal-title":"BMC Neurol"},{"issue":"1","key":"4042_CR30","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3390\/ijms25010061","volume":"25","author":"A Tuttolomondo","year":"2023","unstructured":"Tuttolomondo A, Baglio I, Riolo R, Todaro F, Parrinello G, Miceli S et al (2023) Molecular pathogenesis of central and peripheral nervous system complications in anderson-fabry disease. Int J Mol Sci 25(1):61","journal-title":"Int J Mol Sci"},{"issue":"SUPPL. 2","key":"4042_CR31","doi-asserted-by":"publisher","first-page":"S150","DOI":"10.1097\/01.ASN.0000015239.57436.18","volume":"13","author":"EH Kolodny","year":"2002","unstructured":"Kolodny EH, Pastores GM (2002) Anderson-fabry disease: extrarenal, neurologic manifestations. J Am Soc Nephrol 13(SUPPL. 2):S150\u2013S153. https:\/\/doi.org\/10.1097\/01.ASN.0000015239.57436.18","journal-title":"J Am Soc Nephrol"},{"issue":"439","key":"4042_CR32","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1651-2227.2002.tb03108.x","volume":"91","author":"MJ Hilz","year":"2002","unstructured":"Hilz MJ (2002) Evaluation of peripheral and autonomic nerve function in fabry disease. Acta Paediatr Suppl 91(439):38\u201342","journal-title":"Acta Paediatr Suppl"},{"issue":"12","key":"4042_CR33","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/j.cgh.2007.08.012","volume":"5","author":"B Hoffmann","year":"2007","unstructured":"Hoffmann B, Schwarz M, Mehta A, Keshav S (2007) Gastrointestinal symptoms in 342 patients with fabry disease: prevalence and response to enzyme replacement therapy. Clin Gastroenterol Hepatol 5(12):1447\u20131453","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"4042_CR34","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/mus.10236","volume":"26","author":"CA Luciano","year":"2002","unstructured":"Luciano CA, Russell JW, Banerjee TK, Quirk JM, Scott LJC, Dambrosia JM et al (2002) Physiological characterization of neuropathy in fabry\u2019s disease. Muscle Nerve 26(5):622\u2013629","journal-title":"Muscle Nerve"},{"issue":"4","key":"4042_CR35","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1001\/archneur.1963.00460100061007","volume":"9","author":"AN Rahman","year":"1963","unstructured":"Rahman AN, Lindenberg R (1963) The neuropathology of hereditary dystopic lipidosis. Arch Neurol 9(4):373\u2013385","journal-title":"Arch Neurol"},{"issue":"6","key":"4042_CR36","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3390\/jpm13060904","volume":"13","author":"G Gambini","year":"2023","unstructured":"Gambini G, Scartozzi L, Giannuzzi F, Carl\u00e0 MM, Boselli F, Caporossi T et al (2023) Ophthalmic manifestations in fabry disease. J Pers Med 13(6):904. https:\/\/doi.org\/10.3390\/jpm13060904","journal-title":"J Pers Med"},{"issue":"3","key":"4042_CR37","doi-asserted-by":"publisher","first-page":"e0120814","DOI":"10.1371\/journal.pone.0120814","volume":"10","author":"S Pitz","year":"2015","unstructured":"Pitz S, Kalkum G, Arash L, Karabul N, Sodi A, Larroque S et al (2015) Ocular signs correlate well with disease severity and genotype in fabry disease. PLoS ONE 10(3):e0120814","journal-title":"PLoS ONE"},{"issue":"1","key":"4042_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-022-02392-9","volume":"17","author":"M Beck","year":"2022","unstructured":"Beck M, Ramaswami U, Hernberg-St\u00e5hl E, Hughes DA, Kampmann C, Mehta AB et al (2022) Twenty years of the fabry outcome survey (FOS) insights, achievements, and lessons learned from a global patient registry. Orphanet J Rare Dis 17(1):1\u201314. https:\/\/doi.org\/10.1186\/s13023-022-02392-9","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"4042_CR39","doi-asserted-by":"publisher","first-page":"569","DOI":"10.2215\/CJN.09480819","volume":"15","author":"E Svarstad","year":"2020","unstructured":"Svarstad E, Marti HP (2020) The changing landscape of fabry disease. Clin J Am Soc Nephrol 15(4):569\u2013576","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"4042_CR40","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1681\/ASN.2020071077","volume":"32","author":"CL Ramspek","year":"2021","unstructured":"Ramspek CL, Evans M, Wanner C, Drechsler C, Chesnaye NC, Szymczak M et al (2021) Kidney failure prediction models: a comprehensive external validation study in patients with advanced CKD. J Am Soc Nephrol 32(5):1174\u20131186","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"4042_CR41","doi-asserted-by":"publisher","first-page":"e0230020","DOI":"10.1371\/journal.pone.0230020","volume":"15","author":"M Provenzano","year":"2020","unstructured":"Provenzano M, Rivoli L, Garofalo C, Faga T, Pelagi E, Perticone M et al (2020) Renal resistive index in chronic kidney disease patients: possible determinants and risk profile. PLoS ONE 15(4):e0230020","journal-title":"PLoS ONE"},{"issue":"11","key":"4042_CR42","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","volume":"11","author":"S Waldek","year":"2009","unstructured":"Waldek S, Patel MR, Banikazemi M, Lemay R, Lee P (2009) Life expectancy and cause of death in males and females with fabry disease: findings from the fabry Registry. Genet Med 11(11):790\u2013796","journal-title":"Genet Med"},{"issue":"4","key":"4042_CR43","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/cge.12386","volume":"86","author":"A Pisani","year":"2014","unstructured":"Pisani A, Visciano B, Imbriaco M, Di Nuzzi A, Mancini A, Marchetiello C et al (2014) The kidney in fabry\u2019s disease. Clin Genet 86(4):301\u2013309","journal-title":"Clin Genet"},{"issue":"12","key":"4042_CR44","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1136\/jmedgenet-2015-103471","volume":"52","author":"DG Warnock","year":"2015","unstructured":"Warnock DG, Thomas CP, Vujkovac B, Campbell RC, Charrow J, Laney DA et al (2015) Antiproteinuric therapy and fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy. J Med Genet 52(12):860\u2013866","journal-title":"J Med Genet"},{"key":"4042_CR45","unstructured":"Mehta A, Hughes DA. Fabry Disease. Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, et al. (2023) editors. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1292\/"},{"issue":"9","key":"4042_CR46","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1097\/JCMA.0000000000000379","volume":"83","author":"WT Wang","year":"2020","unstructured":"Wang WT, Sung SH, Liao JN, Hsu TR, Niu DM, Yu WC (2020) Cardiac manifestations in patients with classical orcardiac subtype of Fabry disease. J Chin Med Assoc 83(9):825\u2013829. https:\/\/doi.org\/10.1097\/JCMA.0000000000000379 (PMID: 32649415; PMCID: PMC7478196)","journal-title":"J Chin Med Assoc"},{"issue":"2","key":"4042_CR47","first-page":"S113","volume":"114","author":"A Thomas","year":"2015","unstructured":"Thomas A, Baker R, Mehta A, Hughes D (2015) The N215S mutation results in a distinct subtype of fabry disease. Mol Genet Metab 114(2):S113","journal-title":"Mol Genet Metab"},{"key":"4042_CR48","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.addr.2017.05.004","volume":"118","author":"M Solomon","year":"2017","unstructured":"Solomon M, Muro S (2017) Lysosomal enzyme replacement therapies: historical development, clinical outcomes, and future perspectives. Adv Drug Deliv Rev 118:109\u2013134","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"4042_CR49","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ymgme.2014.01.014","volume":"111","author":"SM Sirrs","year":"2014","unstructured":"Sirrs SM, Bichet DG, Casey R, Clarke JTR, Lemoine K, Doucette S et al (2014) Outcomes of patients treated through the Canadian fabry disease initiative. Mol Genet Metab 111(4):499\u2013506","journal-title":"Mol Genet Metab"},{"issue":"2","key":"4042_CR50","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jmb.2004.01.035","volume":"337","author":"SC Garman","year":"2004","unstructured":"Garman SC, Garboczi DN (2004) The molecular defect leading to fabry disease: structure of human \u03b1-galactosidase. J Mol Biol 337(2):319\u2013335","journal-title":"J Mol Biol"},{"issue":"1","key":"4042_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-015-0253-6","volume":"10","author":"M Biegstraaten","year":"2015","unstructured":"Biegstraaten M, Arngr\u00edmsson R, Barbey F, Boks L, Cecchi F, Deegan PB et al (2015) Recommendations for initiation and cessation of enzyme replacement therapy in patients with fabry disease: the European fabry working group consensus document. Orphanet J Rare Dis 10(1):1\u201310","journal-title":"Orphanet J Rare Dis"},{"key":"4042_CR52","unstructured":"Mehta A, Hughes DA. Fabry Disease. Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, et al. (2023)editors. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1292\/"},{"issue":"2","key":"4042_CR53","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ymgme.2017.05.001","volume":"121","author":"M Arends","year":"2017","unstructured":"Arends M, Wijburg FA, Wanner C, Vaz FM, van Kuilenburg ABP, Hughes DA, Biegstraaten M, Mehta A, Hollak CEM, Langeveld M (2017) Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease. Mol Genet Metab 121(2):157\u2013161. https:\/\/doi.org\/10.1016\/j.ymgme.2017.05.001 (PMID: 28495078)","journal-title":"Mol Genet Metab"},{"issue":"2","key":"4042_CR54","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ymgme.2012.12.005","volume":"108","author":"BE Smid","year":"2013","unstructured":"Smid BE, Hoogendijk SL, Wijburg FA, Hollak CEM, Linthorst GE (2013) A revised home treatment algorithm for fabry disease: influence of antibody formation. Mol Genet Metab 108(2):132\u2013137","journal-title":"Mol Genet Metab"},{"issue":"4","key":"4042_CR55","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","volume":"66","author":"GE Linthorst","year":"2004","unstructured":"Linthorst GE, Hollak CEM, Donker-Koopman WE, Strijland A, Aerts JMFG (2004) Enzyme therapy for fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int 66(4):1589\u20131595","journal-title":"Kidney Int"},{"issue":"9","key":"4042_CR56","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1681\/ASN.2018030329","volume":"29","author":"M Lenders","year":"2018","unstructured":"Lenders M, Brand E (2018) Effects of enzyme replacement therapy and antidrug antibodies in patients with fabry disease. J Am Soc Nephrol 29(9):2265\u20132278","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"4042_CR57","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ymgme.2018.11.008","volume":"126","author":"SJ van der Veen","year":"2019","unstructured":"van der Veen SJ, van Kuilenburg ABP, Hollak CEM, Kaijen PHP, Voorberg J, Langeveld M (2019) Antibodies against recombinant alpha-galactosidase a in fabry disease: subclass analysis and impact on response to treatment. Mol Genet Metab 126(2):162\u2013168","journal-title":"Mol Genet Metab"},{"issue":"1","key":"4042_CR58","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1681\/ASN.2014121226","volume":"27","author":"M Lenders","year":"2016","unstructured":"Lenders M, Stypmann J, Duning T, Schmitz B, Brand SM, Brand E (2016) Serum-mediated inhibition of enzyme replacement therapy in fabry disease. J Am Soc Nephrol 27(1):256\u2013264","journal-title":"J Am Soc Nephrol"},{"issue":"13","key":"4042_CR59","doi-asserted-by":"publisher","first-page":"1024963","DOI":"10.3389\/fimmu.2022.1024963","volume":"9","author":"M Lenders","year":"2022","unstructured":"Lenders M, Brand E (2022) Assessment and impact of dose escalation on anti-drug antibodies in fabry disease. Front Immunol 9(13):1024963","journal-title":"Front Immunol"},{"issue":"3","key":"4042_CR60","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/joim.12647","volume":"282","author":"M Lenders","year":"2017","unstructured":"Lenders M, Oder D, Nowak A, Canaan-K\u00fchl S, Arash-Kaps L, Drechsler C et al (2017) Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with fabry disease. J Intern Med 282(3):241\u2013253. https:\/\/doi.org\/10.1111\/joim.12647","journal-title":"J Intern Med"},{"issue":"6","key":"4042_CR61","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1510198","volume":"375","author":"DP Germain","year":"2016","unstructured":"Germain DP, Hughes DA, Nicholls K, Bichet DG, Giugliani R, Wilcox WR et al (2016) Treatment of fabry\u2019s disease with the pharmacologic chaperone migalastat. N Engl J Med 375(6):545\u2013555","journal-title":"N Engl J Med"},{"issue":"1\u20132","key":"4042_CR62","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ymgme.2020.07.007","volume":"131","author":"U Feldt-Rasmussen","year":"2020","unstructured":"Feldt-Rasmussen U, Hughes D, Sunder-Plassmann G, Shankar S, Nedd K, Olivotto I et al (2020) Long-term efficacy and safety of migalastat treatment in fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study. Mol Genet Metab 131(1\u20132):219\u2013228","journal-title":"Mol Genet Metab"},{"key":"4042_CR63","unstructured":"Galafold | European Medicines Agency https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/galafold"},{"issue":"3","key":"4042_CR64","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ymgme.2009.10.178","volume":"99","author":"EH Giannini","year":"2010","unstructured":"Giannini EH, Mehta AB, Hilz MJ, Beck M, Bichet DG, Brady RO, West M, Germain DP, Wanner C, Waldek S, Clarke JT, Mengel E, Strotmann JM, Warnock DG, Linhart A (2010) A validated disease severity scoring system for Fabry disease. Mol Genet Metab 99(3):283\u2013290. https:\/\/doi.org\/10.1016\/j.ymgme.2009.10.178 (PMID: 19951842)","journal-title":"Mol Genet Metab"},{"issue":"2","key":"4042_CR65","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ymgme.2014.08.002","volume":"114","author":"T Kizhner","year":"2015","unstructured":"Kizhner T, Azulay Y, Hainrichson M, Tekoah Y, Arvatz G, Shulman A et al (2015) Characterization of a chemically modified plant cell culture expressed human \u03b1-galactosidase-a enzyme for treatment of fabry disease. Mol Genet Metab 114(2):259\u2013267","journal-title":"Mol Genet Metab"},{"issue":"3","key":"4042_CR66","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/jimd.12080","volume":"42","author":"R Schiffmann","year":"2019","unstructured":"Schiffmann R, Goker-Alpan O, Holida M, Giraldo P, Barisoni L, Colvin RB et al (2019) Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1-year Phase 1\/2 clinical trial. J Inherit Metab Dis 42(3):534\u2013544. https:\/\/doi.org\/10.1002\/jimd.12080","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"4042_CR67","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1016\/j.ymgme.2018.12.176","volume":"126","author":"MD Holida","year":"2019","unstructured":"Holida MD, Bernat J, Longo N, Goker-Alpan O, Wallace E, Schiffmann R et al (2019) Once every 4 weeks, 2 mg\/kg of pegunigalsidase alfa is used to treat fabry disease preliminary results of a phase 3 study. Mol Genet Metab 126(2):S73. https:\/\/doi.org\/10.1016\/j.ymgme.2018.12.176","journal-title":"Mol Genet Metab"},{"key":"4042_CR68","doi-asserted-by":"publisher","DOI":"10.1136\/jmg-2023-109818","author":"EL Wallace","year":"2023","unstructured":"Wallace EL, Goker-Alpan O, Wilcox WR, Holida M, Bernat J, Longo N et al (2023) Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with fabry disease and deteriorating renal function: results from the 2-year randomized phase III BALANCE study. J Med Genet. https:\/\/doi.org\/10.1136\/jmg-2023-109818","journal-title":"J Med Genet"},{"key":"4042_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-023-02937-6","author":"A Linhart","year":"2023","unstructured":"Linhart A, Dost\u00e1lov\u00e1 G, Nicholls K, West ML, T\u00f8ndel C, Jovanovic A et al (2023) Safety and efficacy of pegunigalsidase alfa in patients with fabry disease who were previously treated with agalsidase alfa results from BRIDGE a phase 3 open-label study. Orphanet J Rare Dis. https:\/\/doi.org\/10.1186\/s13023-023-02937-6","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"4042_CR70","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s10545-015-9886-9","volume":"39","author":"JS Shen","year":"2016","unstructured":"Shen JS, Busch A, Day TS, Meng XL, Yu CI, Dabrowska-Schlepp P et al (2016) Mannose receptor-mediated delivery of moss-made \u03b1-galactosidase a efficiently corrects enzyme deficiency in fabry mice. J Inherit Metab Dis 39(2):293\u2013303. https:\/\/doi.org\/10.1007\/s10545-015-9886-9","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"4042_CR71","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/jimd.12052","volume":"42","author":"JB Hennermann","year":"2019","unstructured":"Hennermann JB, Arash-Kaps L, Fekete G, Schaaf A, Busch A, Frischmuth T (2019) Pharmacokinetics, pharmacodynamics, and safety of moss-aGalactosidase a in patients with fabry disease. J Inherit Metab Dis 42(3):527\u2013533","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"4042_CR72","doi-asserted-by":"publisher","first-page":"106963","DOI":"10.1016\/j.ymgme.2022.11.002","volume":"138","author":"PB Deegan","year":"2023","unstructured":"Deegan PB, Goker-Alpan O, Geberhiwot T, Hopkin RJ, Lukina E, Tylki-Szymanska A et al (2023) Venglustat, an orally administered glucosylceramide synthase inhibitor: assessment over 3 years in adult males with classic fabry disease in an open-label phase 2 study and its extension study. Mol Genet Metab 138(2):106963","journal-title":"Mol Genet Metab"},{"issue":"4","key":"4042_CR73","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.ajhg.2019.02.003","volume":"104","author":"X Zhu","year":"2019","unstructured":"Zhu X, Yin L, Theisen M, Zhuo J, Siddiqui S, Levy B et al (2019) Systemic mRNA therapy for the treatment of fabry disease: preclinical studies in wild-type mice, fabry mouse model, and wild-type non-human primates. Am J Hum Genet 104(4):625\u2013637","journal-title":"Am J Hum Genet"},{"issue":"4","key":"4042_CR74","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.ymthe.2019.03.001","volume":"27","author":"F DeRosa","year":"2019","unstructured":"DeRosa F, Smith L, Shen Y, Huang Y, Pan J, Xie H et al (2019) Improved efficacy in a fabry disease model using a systemic mrna liver depot system compared to enzyme replacement therapy. Mol Ther 27(4):878\u2013889","journal-title":"Mol Ther"},{"issue":"15","key":"4042_CR75","doi-asserted-by":"publisher","first-page":"7917","DOI":"10.1073\/pnas.93.15.7917","volume":"93","author":"JA Medin","year":"1996","unstructured":"Medin JA, Tudor M, Simovitch R, Quirk JM, Jacobson S, Murray GJ et al (1996) Correction in trans for fabry disease: expression, secretion and uptake of alpha-galactosidase a in patient-derived cells driven by a high-titer recombinant retroviral vector. Proc Natl Acad Sci U S A 93(15):7917\u20137922","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"4042_CR76","doi-asserted-by":"publisher","first-page":"7515","DOI":"10.1073\/pnas.120177997","volume":"97","author":"T Takenaka","year":"2000","unstructured":"Takenaka T, Murray GJ, Qin G, Quirk JM, Ohshima T, Qasba P et al (2000) Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted fabry mice receiving transduced bone marrow cells. Proc Natl Acad Sci U S A 97(13):7515\u20137520","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4042_CR77","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-023-02894-0","author":"M Deng","year":"2023","unstructured":"Deng M, Zhou H, He S, Qiu H, Wang Y, Zhao AY et al (2023) Systematic gene therapy derived from an investigative study of AAV2\/8 vector gene therapy for fabry disease. Orphanet J Rare Dis. https:\/\/doi.org\/10.1186\/s13023-023-02894-0","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"4042_CR78","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1681\/ASN.2006121400","volume":"18","author":"H Tahir","year":"2007","unstructured":"Tahir H, Jackson LL, Warnock DG (2007) Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-\u03b2. J Am Soc Nephrol 18(9):2609\u20132617","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"4042_CR79","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3390\/medicina55060268","volume":"55","author":"C Garofalo","year":"2019","unstructured":"Garofalo C, Borrelli S, Liberti M, Andreucci M, Conte G, Minutolo R et al (2019) SGLT2 Inhibitors: nephroprotective efficacy and side effects. Medicina 55(6):268","journal-title":"Medicina"},{"issue":"11","key":"4042_CR80","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.3390\/jcm12113689","volume":"12","author":"Y Battaglia","year":"2023","unstructured":"Battaglia Y, Bulighin F, Zerbinati L, Vitturi N, Marchi G, Carraro G (2023) Dapaglifozin on albuminuria in chronic kidney disease patients with fabry disease: the defy study design and protocol. J Clin Med 12(11):3689","journal-title":"J Clin Med"},{"issue":"11","key":"4042_CR81","doi-asserted-by":"publisher","DOI":"10.1172\/JCI157782","volume":"133","author":"F Braun","year":"2023","unstructured":"Braun F, Abed A, Sellung D, Rogg M, Woidy M, Eikrem O, Wanner N, Gambardella J, Laufer SD, Haas F, Wong MN, Dumoulin B, Rischke P, M\u00fchlig A, Sachs W, von Cossel K, Schulz K, Muschol N, Gersting SW, Muntau AC, Kretz O, Hahn O, Rinschen MM, Mauer M, Bork T, Grahammer F, Liang W, Eierhoff T, R\u00f6mer W, Hansen A, Meyer-Schwesinger C, Iaccarino G, T\u00f8ndel C, Marti HP, Najafian B, Puelles VG, Schell C, Huber TB (2023) Accumulation of \u03b1-synuclein mediates podocyte injury in Fabry nephropathy. J Clin Invest 133(11):e157782. https:\/\/doi.org\/10.1172\/JCI157782 (PMID: 37014703; PMCID: PMC10232004)","journal-title":"J Clin Invest"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-024-04042-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-024-04042-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-024-04042-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T16:28:43Z","timestamp":1726504123000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-024-04042-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,13]]},"references-count":81,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["4042"],"URL":"https:\/\/doi.org\/10.1007\/s11255-024-04042-4","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,13]]},"assertion":[{"value":"15 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors declare that they have no relevant conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}